Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ta-8995
1. Ta-8995
2. 866399-87-3
3. Obicetrapib (free Base)
4. Amg-899
5. Dez-001
6. Obicetrapib [inn]
7. 8o74k609hn
8. 866399-87-3 (free Base)
9. (2r,4s)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(3-carboxypropoxy)pyrimidin-2-yl)amino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2h-quinoline-1-carboxylic Acid Ethyl Ester
10. 1(2h)-quinolinecarboxylic Acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-ethyl Ester, (2r,4s)-
11. 1-ethyl (2r,4s)-4-[[[3,5-bis(trifluoromethyl)phenyl]methyl][5-(3-carboxypropoxy)-2-pyrimidinyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2h)-quinolinecarboxylate
12. 4-((2-(((3,5-bis(trifluoromethyl)phenyl)methyl)((2r,4s)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- Tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic Acid
13. 4-((2-((3,5-bis(trifluoromethyl)benzyl)((2r,4s)-1-(ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic Acid
14. 4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2r,4s)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic Acid
15. Obicetrapib [who-dd]
16. Unii-8o74k609hn
17. Chembl3785197
18. Schembl17002081
19. Gtpl12205
20. Ex-a6112
21. Ta8995
22. Obicetrapib (amg-899,ta-8995)
23. Db14890
24. Ac-35552
25. Hy-18778
26. Q27270811
| Molecular Weight | 722.6 g/mol |
|---|---|
| Molecular Formula | C32H31F9N4O5 |
| XLogP3 | 7.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 12 |
| Exact Mass | 722.21507356 g/mol |
| Monoisotopic Mass | 722.21507356 g/mol |
| Topological Polar Surface Area | 105 Ų |
| Heavy Atom Count | 50 |
| Formal Charge | 0 |
| Complexity | 1100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Obicetrapib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Obicetrapib, including repackagers and relabelers. The FDA regulates Obicetrapib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Obicetrapib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Obicetrapib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Obicetrapib supplier is an individual or a company that provides Obicetrapib active pharmaceutical ingredient (API) or Obicetrapib finished formulations upon request. The Obicetrapib suppliers may include Obicetrapib API manufacturers, exporters, distributors and traders.
click here to find a list of Obicetrapib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Obicetrapib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Obicetrapib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Obicetrapib GMP manufacturer or Obicetrapib GMP API supplier for your needs.
A Obicetrapib CoA (Certificate of Analysis) is a formal document that attests to Obicetrapib's compliance with Obicetrapib specifications and serves as a tool for batch-level quality control.
Obicetrapib CoA mostly includes findings from lab analyses of a specific batch. For each Obicetrapib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Obicetrapib may be tested according to a variety of international standards, such as European Pharmacopoeia (Obicetrapib EP), Obicetrapib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Obicetrapib USP).
LOOKING FOR A SUPPLIER?
